Cargando…

Clinical Therapeutics in Pregnancy

Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Feghali, Maisa N., Mattison, Donald R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139199/
https://www.ncbi.nlm.nih.gov/pubmed/21785566
http://dx.doi.org/10.1155/2011/783528
_version_ 1782208435566149632
author Feghali, Maisa N.
Mattison, Donald R.
author_facet Feghali, Maisa N.
Mattison, Donald R.
author_sort Feghali, Maisa N.
collection PubMed
description Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy.
format Online
Article
Text
id pubmed-3139199
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-31391992011-07-22 Clinical Therapeutics in Pregnancy Feghali, Maisa N. Mattison, Donald R. J Biomed Biotechnol Review Article Most drugs are not tested for use during pregnancy, consequently, labeling, which may include information about fetal safety, includes nothing about dosing, efficacy, or maternal safety. Yet these are concerns of health care providers considering treatment of disease during pregnancy. Therefore, the practitioner treats the pregnant woman with the same dose recommended for use in adults (typically men) or may decide not to treat the disease at all. However, is the choice of not treating a woman during pregnancy better than dealing with the challenges which accompany treatment? This paper, which summarizes metabolic and physiologic changes induced by pregnancy, illustrates that standard adult dosing is likely to be incorrect during pregnancy. Hindawi Publishing Corporation 2011 2011-07-06 /pmc/articles/PMC3139199/ /pubmed/21785566 http://dx.doi.org/10.1155/2011/783528 Text en Copyright © 2011 M. N. Feghali and D. R. Mattison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Feghali, Maisa N.
Mattison, Donald R.
Clinical Therapeutics in Pregnancy
title Clinical Therapeutics in Pregnancy
title_full Clinical Therapeutics in Pregnancy
title_fullStr Clinical Therapeutics in Pregnancy
title_full_unstemmed Clinical Therapeutics in Pregnancy
title_short Clinical Therapeutics in Pregnancy
title_sort clinical therapeutics in pregnancy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139199/
https://www.ncbi.nlm.nih.gov/pubmed/21785566
http://dx.doi.org/10.1155/2011/783528
work_keys_str_mv AT feghalimaisan clinicaltherapeuticsinpregnancy
AT mattisondonaldr clinicaltherapeuticsinpregnancy